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ORIGINAL ARTICLE
Survey and Biological Insights of Pemetrexed-Related
Therapeutic Improvement in Mesothelioma
The Nancy Centre of Biological Resources’ Mesothelioma Cohort
Fotis Vlastos, MD,*† Georgios Hillas, MD,*† Philippe Vidal, PhD,* Ste´phanie Lacomme, Mrs,*
Franc¸oise Galateau-Salle´, MD,‡ Ekkehard Vollmer, MD,§ Josune Guzman-Costabel, MD,
Jean Michel Vignaud, MD,* and Nadine Martinet, MD*
Introduction: We report a survey of mesothelioma survival rates
with insights into the survival benefit because of pemetrexed. We
also studied a potential link between specific single nucleotide
polymorphisms of transcobalamin II (TCII) gene and susceptibility
to both asbestos and pemetrexed.
Methods: Clinical and occupational data from 287 consecutive
mesothelioma patients were collected from the north-east region of
France (1989–2007). Blood or paired tumoral and normal samples
were collected from the last 210 French patients to study the TCII
single nucleotide polymorphisms at the codon 259 (quantitative
polymerase chain reaction). Results were compared with those
obtained from a group of 263 French control healthy subjects and to
a group of 91 German mesothelioma patients. Patients’ characteris-
tics and genotypes results were statistically analyzed for significant
correlations.
Results: The mean overall patient’s survival was 18.19  21.07
months. Pemetrexed increased the patients’ survival by 50% (21.81
versus 16.99 months). The TCII allele Proline (Pro) was overrepre-
sented into the mesothelioma cohort when compared with the
controls (35 versus 19.77%). This also concerned German patients.
The alleles Pro and Proline Arginine (ProArg) were more frequent
among patients exposed to asbestos (p  0.005, p  0.001, respec-
tively). The allele ProArg was associated with the longest survival
while under pemetrexed (p 0.007). No difference was found in the
genotypes of patients untreated with pemetrexed.
Conclusions: Pemetrexed treatment is related to a survival increase
in mesothelioma patients. The allele Pro seems overrepresented in
mesothelioma patients. Those having the allele ProArg present a
better outcome under pemetrexed.
Key Words: Mesothelioma, Pemetrexed, Transcobalamin II, Al-
leles, Survival.
(J Thorac Oncol. 2009;4: 1259–1263)
Mesothelioma is a particularly aggressive type of tumorassociated with therapeutic resistance and poor prog-
nosis.1 Its incidence is expected to rise in Europe during the
next two decades, as a result of past or ongoing asbestos
exposure.2 Many epidemiological studies have confirmed the
relation between asbestos exposure and mesothelioma inci-
dence, but the prognostic factors for asbestos-exposed me-
sothelioma patients’ survival remain a matter of research.3–6
The overall survival of mesothelioma patients has been shown to
correlate with histologic subtype (the epithelial type being more
favorable), performance status, and disease extent.7
Pemetrexed, a new generation antifolate that was re-
cently introduced as a chemotherapeutic agent against me-
sothelioma, has been shown to improve patients’ survival.8
This drug inhibits the thymidilate synthase, a key enzyme for
the intracellular de novo production of purines.9 Neverthe-
less, the outcome varies among pemetrexed-treated pa-
tients.10,11 The prognosis of the outcome remains uncertain
because no clinical or molecular marker has been yet linked
to the efficacy of this drug.
The Nancy “Centre of Biologic Resources” (“Centre
des Ressources Biologiques”) is an ISO 9001–2000 certified
biobank with biologic material and follow-up data from
French lung cancer and mesothelioma patients collected for
the last 20 years. This allows for a survey of mesothelioma
survival rates and impact of new treatment containing an
antifolate (pemetrexed).
Pemetrexed, as all the antifolates, suppresses the effects
of folic acid and its derivatives on cellular processes in which
they play a role.12 Therefore, it produces a state of intracel-
lular folic acid deficiency that influences DNA mitosis, a
main pathologic feature of cancer.13 To explain the benefit of
pemetrexed among treated patients, patients’ DNA were
screened for single nucleotide polymorphism (SNPs) of
transcobalamin II (TCII), a key factor of folates metabolism.
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Data were compared with a control cohort of French healthy
subjects and to a group of German patients with mesothelioma.
We hypothesized that mesothelioma patients’ genetic
profile concerning the folate metabolism may influence on the
outcome of the treatment with pemetrexed.
PATIENTS AND METHODS
A cohort of 287 consecutive French mesothelioma
patients has been accrued from October 1989 to January
2007. Registered characteristics were age, gender, smoking
history, tobacco consumption (pack/years), age of beginning
and ending of smoking, exposition to asbestos with age of
onset and overall duration, histologic subtype of mesotheli-
oma, and treatment modalities (surgery, chemotherapy with
or without pemetrexed, or palliative care alone). Survival was
counted in months from the day of diagnosis (date of thora-
coscopy) to the day of death and was statistically analyzed.
Survival rates of patients treated or untreated with a pem-
etrexed-containing regimen were compared. Independent
factors were also analyzed for statistical significance on
survival: age, tobacco consumption, asbestos exposure,
pleural plaques, and histology. TCII SNPs at the codon 259
were assessed by quantitative polymerase chain reaction in a
subgroup of 210 of the 287 French mesothelioma patients
(Table 1) for which peripheral blood DNA was systematically
purified after 1994. Results were compared first with those
obtained from a group of 263 French control healthy subjects,
matched in age and sex, and second with a group of 91
German mesothelioma patients for which there was no clin-
ical data available. All cases were certified by the French
experts from the mesothelioma panel.
Analysis of survival was based on Kaplan-Meier meth-
odology. The characteristics of the subjects were compared
using log-rank test for numerous samples and 2 test for
paired values. Statistica software (Statsoft) was used for the
above mentioned analyses.
RESULTS
General Presentation of the French
Mesothelioma Cohort
Patients’ characteristics are presented in Table 2. As-
bestos exposure was present for 80.7% of the male patients
and for 30% of the female patients. The mean age (SD) of
the first exposure to asbestos was 21.66 (6.68) years for
men and 22.75 (5.10) years for women. The mean duration
of exposure was 17.67 (13.89) years for men and 4.19
(8.61) years for women. The incidence of mesothelioma
histotypes was 60% for the epithelial, 21% for the mixed
(biphasic), 9% for the sarcomatous, and 2.8% for the desmo-
plastic subtype. Nine patients suffered from atypical me-
sothelial hyperplasia, and six patients had peritoneal me-
sothelioma. A minority of the patients (12.9%, n  37) were
surgically treated (either by decortication or pleuropneumo-
nectomy). Moreover, 21.95% of them (n  63) received a
chemotherapy regimen containing pemetrexed because it was
only introduced in 2002.
The mean (SD) overall survival rate of the cohort was
18.19 (21.07) months. Long survivors (5 years) were rare
(5/287). Survival was correlated to histology, as patients with
atypical mesothelial hyperplasia or the epithelial type showed
a statistically longer survival comparing with the other his-
TABLE 1. Preparation of the Reactive Mixture and Programme of PCR During the
Quality Control (Amplification of TCII Gene)
Reactive Mix
Composition Concentration/Final Quantity
Absolut SYBR GREEN 2 1
Primer CAS or SIS (10 M) 0.1 M
Primer common ERGE (10 M) 0.1 M
DNA 50 ng of DNA
Distilled water qsp 10 L
PCR Programme
Cycle Repetitions Duration (min) Temperature (°C)
1 1 15:00 95
2 40 00:20 94
00:20 63
00:20 72
3 1 00:05 95
4 60 00:15 65  fusion curve with rise of temperature of 0.5°C/cycle
5 1 00:30 20
Sequences of primers
CAS: CTC ATG ACT TCC CCC ATG CC 757-776	 PRO, 259 PB
ERGE: TGC CAG ACA GTC TGG GAA GA 914-933	
SIS: CTC ATG ACT TCC CCC ATG CG 757-776	 ARG, 176 PB
PCR, polymerase chain reaction; PB, international measurement unit for primers length.
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tologic subtypes (p  0.001; Figure 1). Exposure to asbestos
was not found to prognoses survival (p 0.51). The duration
of exposure to asbestos and the age of exposition onset were
not correlated to the age of diagnosis. The presence of pleural
plaques was also not correlated to survival (p  0.33).
Comparison between treated and nontreated patients with
pemetrexed showed a statistically significant longer survival
in favor of the pemetrexed-treated group (p  0.001; Figure
2). The mean survival in pemetrexed-treated patients was
21.81 (20.33) months, whereas that of the patients without
a pemetrexed-containing regimen was 16.99 (21.52)
months.
TCII SNPs assessment at the codon 259 of French
mesothelioma patients were as follows: ProArg 55, Pro 35,
and Arg 10%, whereas the percentages among control sub-
jects were as follows: ProArg 61.21, Pro 19.77, and Arg
19.01%. The Pro genotype percentage among mesothelioma
patients was significantly higher when comparing with the
control population 2  7.78, p  0.005). Moreover, Pro and
ProArg genotypes were found to be more common among the
asbestos-exposed patients (2  7.82, p  0.005 and 2 
19.36, p  0.001, respectively). The genotyping profile of
French mesothelioma patients did not differ from that of the
German patients: ProArg 53.61, Pro 29.34, and Arg 16.3%.
FIGURE 1. Survival curves in histologic sub-
groups of mesothelioma patients.
TABLE 2. Epidemiological Description of the Cohort
Age (yr)
Smoking
Habits (py)
Exposure
(n, %)
Age of Exposure
Onset (yr)
Duration of
Exposure (yr)
Histological
Subtypes
(n, %)
Surgical
Treatment (n, %)
Pemetrexed-Containing
Regimen (n,%)
Men 234 66.09  10.85 22.33  26.84 189 (80.7) 21.66 (6.68) 17.67  13.89 MME 146 33 (14.1) 53 (22.65)
MMS 19
MMM 49
MMD 6
AMH 9
Women 53 64.85  12.44 2.17  6.85 16 (30) 22.75 (5.10) 4.19  8.61 MME 27 4 (7.54) 10 (18.87)
MMS 7
MMM 11
MMD 2
AMH 2
Total 287 65.87  11.15 18.64  25.61 205 (71.4) 21.73 (6.58) 15.22  14.08 MME 175 37 (12.9) 63 (21.95)
MMS 26
MMM 60
MMD 8
AMH 11
PM 6
MME, malignant mesothelioma epithelial type; MMS, malignant mesothelioma sarcomatous type; MMM, malignant mesothelioma mixed type; MMD, malignant mesothelioma
desmoplastic type; AMH, atypical mesothelial hyperplasia; PM, peritoneal mesothelioma.
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Moreover, the genotypes of the cohort were not correlated to
overall survival (2: 1.99, p  0.36; Figure 3).
The ProArg genotype was significantly associated with
an improved outcome after treatment with pemetrexed (2:
9.88, p  0.007), whereas no correlation was found between
TCII-related genotypes and survival among nontreated with
pemetrexed patients (2: 1.99, p  0.36). The mean survival
of pemetrexed-treated patients was 26.47 (24.11) months
for the ProArg subgroup (n  34), 18.54 (13.73) months
for the Pro subgroup (n 22), and 14 (8.72) months for the
Arg group (n  4). Asbestos exposure was not found to be
associated with the overall survival of our patients.
DISCUSSION
Although exposure to asbestos has been definitely as-
sociated with the development of mesothelioma, the specific
characteristics of this exposure seem to be of no further
prognostic importance.14 Moreover, there are contradictory
reports concerning the influence of asbestos exposure on
survival.15,16 This may be because of difficulties in profes-
sional questionnaires and absence of mineralogical studies in
lung tissues of mesothelioma patients.17 We found no rela-
tionship between asbestos exposure and the age of diagnosis
or the overall survival after the diagnosis of mesothelioma.
Moreover, pleural plaques cannot serve as a trustworthy
predictor of the tumorogenic action of asbestos fibers.
Pemetrexed was found to be related with a better
outcome comparing with nonpemetrexed-treated mesotheli-
oma patients. As this study is not a clinical trial, many factors
may have influenced this finding. Nevertheless, pemetrexed
may be considered as a promising therapeutic possibility for
patients with such an aggressive malignancy.
A common polymorphism (776 CG) in the vitamin
B12 transport protein TCII has been identified in which
Proline replaces Arginine at codon 259.18 Our study reports a
higher incidence of the Pro genotype among mesothelioma
patients when comparing with a matched control population.
As TCII is the major folate carrier in the organism, polymor-
phisms capable of modifying the transport capacity of this
glycoprotein are expected to influence the mesothelial cellu-
lar functions in chronic inflammatory conditions and the
intracellular activity of antifolates. Subjects homozygous for
the Proline form of TCII (Pro) compared with those homozy-
gous for the Arginine form (Arg) or with heterozygotes
(ProArg) may have a more efficient folate transport. The
increased levels of vitamin B12 may influence the intracel-
lular “methylation ratio” and subsequent DNA methylation.
The “methylation ratio Sadenosylmethionine/S-adenosylho-
FIGURE 2. Comparison of survival of patients who received
a pemetrexed containing regimen (red spots) versus those
who had not (blue spots).
FIGURE 3. Comparison of survival curves be-
tween transcobalamin II genotypes in mesothe-
lioma patients.
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mocysteine (SAH)” was reported to be lower in colon cancer
versus normal mucosa, mainly because of a much higher
S-adenosylhomocysteine concentration.19 Moreover, among
24 nonsynonymous SNPs in 13 genes related to the one-
carbon metabolism pathway, an increased risk for colorectal
adenoma was reported only for carriers of the ProArg variant.20
We found that TCII Pro and ProArg genotypes were
more frequent among our asbestos-exposed patients. This
may indicate a genetic predisposition of these subjects to
develop mesothelioma. The level of cellular folates is an
important determinant of the activity of pemetrexed.21 When
the folate transport function is decreased, the pemetrexed
inhibition at the level of glycinamide ribonucleotide trans-
ferase, a purine biosynthetic enzyme, is enhanced.22 Apart
from the well-documented therapeutic benefit of pemetrexed
in mesothelioma, this study may provide a new insight
concerning the biologic profile of pemetrexed-treated patients
who gain more from this treatment. Among the carriers of a
SNP of TCII, those with a ProArg genotype seem to present
a better outcome under pemetrexed.
This study presents the limitation of relatively small
studied cohorts. Nevertheless, the rarity of mesothelioma and
the lack of knowledge concerning its pathophysiologic mech-
anisms render the aforementioned findings worth to be taken
into account for future studies.
Cohorts of mesothelioma offer a unique possibility to
study the clinical, pathologic, and therapeutic evolution of
this aggressive tumor. Coupled with biologic data analysis,
this procedure may offer new insights into the natural course
and new directions for the prophylaxis and the management
of the disease. The study of TCII SNPs offers a paradigm of
the involvement of folates metabolism in the pathophysio-
logic mechanisms of mesothelial carcinogenesis and in the
therapeutic action of antifolate drugs. This allele encodes an
enzyme not very efficient for vitamin B12 intake. Wider
studies should be undertaken onto systematic genotyping of
all the enzymes involved into folates metabolism in patients
with mesothelioma.
CONCLUSIONS
Mesothelioma remains a highly aggressive tumor. Pem-
etrexed do offer a measurable survival gain to mesothelioma
patients. TCII genotype differs between healthy subjects and
mesothelioma patients. The allele Pro seems more frequent in
French patients and this remains true for German patients
also. At least for the French ones, patients with the allele
ProArg are presenting a better outcome under pemetrexed.
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